StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BioMarin Pharma (BMRN) Will Seek Review of PTAB Exon 51 Composition of Matter Patent Decision (SRPT)
September 21, 2016 8:55 AM
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it intends to seek a review of the Patent Trial and Appeal Board ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
Litigation
Next Articles
BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics
September 21, 2016 8:54 AM
Baird Affirms Sarepta Therapeutics (SRPT) at 'Outperform'; Incrementally Positive on PTAB Decision (BMRN)
September 21, 2016 6:26 AM
Sarepta Therapeutics (SRPT) Says USPTO Issued Favorable Decisions on Exon 51 and Exon 53 Composition in Case vs BioMarin (BMRN)
September 20, 2016 5:17 PM
Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
September 20, 2016 1:18 PM
Form 4 BIOMARIN PHARMACEUTICAL For: Sep 15 Filed by: BIENAIME JEAN JACQUES
September 19, 2016 6:42 PM